Japanese Population Norms for Preference-Based Measures: Eq-5d-3l, Eq-5d-5l, And Sf-6d

Shiroiwa, Takeru; Fukuda, Takashi; Ikeda, Shunya; Igarashi, Ataru; Noto, Shinichi; Shimozuma, Kojiro

doi:10.1016/j.jval.2015.09.2830

Cited by 50 publications

(72 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A key problem for the EQ-5D-3L is its tendency to generate significant 'ceiling effects' whereby a high proportion of respondents report having 'no problems' on all or one domain [3]. In line with previous studies using general population samples, we found a 10.6 percentage point fall in full health (no problems on all domains) reported for the EQ-5D-5L versus the EQ-5D-3L [5,20,21]. A similar phenomenon for the EQ-5D-3L, although not noted in the current literature, is the tendency for respondents to report 'some problems' in any or all health domains, despite also reporting having no ongoing health conditions.…”

Section: Discussionsupporting

confidence: 88%

A Comparison of the EQ-5D-3L and EQ-5D-5L

Thompson

Turner

2020

PharmacoEconomics

View full text Add to dashboard Cite

Introduction The EQ-5D-3L (3L) and EQ-5D-5L (5L) are both frequently used measures of health status. Previous studies have found the EQ-5D-5L to have superior measurement properties but no study has compared the two measures in a large general population survey using matched respondents. Methods Using data from the GP Patient Survey, coarsened exact matching was used to match individuals completing the 3L in 2011 with those completing the 5L in 2012. Measurement properties were assessed for a general population and multimorbid population (chronic conditions ≥ 2), with ceiling effects, informativity and distribution of response compared. Changes in the direction of response, as well as the impact on utility distributions, were quantified. Results Matching resulted in a cohort of 1, 023,218 respondents (2011: 511,609; 2012: 511,609) for analysis. Ceiling effects for the 5L were lower than the 3L (43.8% vs. 54.4%). The 5L had improved informativity and broader spread of responses than the 3L (5L top 50 profiles: 77.4% vs. 3L: 98.8%). Overall, there was an upwards shift in utility values for the 5L versus the 3L as respondents using the 5L reported ill health more frequently but with less severity. Measurement improvements and effects on utility values were more pronounced for the multimorbid population. Conclusion The 5L had superior measurement properties than the 3L and should be preferred in general population surveys and for use in individuals with multimorbidity. At increasing levels of morbidity, the 5L is currently associated with higher utility values than the 3L. Electronic supplementary material The online version of this article (https ://doi.The EQ-5D-5L has superior measurement properties to the EQ-5D-3L and should be preferred in general population and multimorbid populations.The EQ-5D-5L leads respondents to report more illhealth. However, it is less severe than when using the EQ-5D-3L.For higher-levels of multimorbidity, use of the EQ-5D-5L in England will currently lead to higher utility values than the EQ-5D-3L, irrespective of the tariff used.

show abstract

Section: Discussionsupporting

confidence: 88%

A Comparison of the EQ-5D-3L and EQ-5D-5L

Thompson

Turner

2020

PharmacoEconomics

View full text Add to dashboard Cite

show abstract

“…31 The Japanese researchers Shiroiwa et al also reported that there was a difference between the utility scores for the general population in Japan and the other countries. 32 Those findings, however, come from general or mild health condition of patients. It is conjectured that, specific to countries, the utility scores differ in severe conditions more largely than in mild ones.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan

Kamae

Hashimoto

Koretsune

et al. 2015

Clinical Therapeutics

View full text Add to dashboard Cite

Although most participants in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial used for the efficacy data of apixaban in the model were non-Japanese patients, the impact of the limitations on our results was considered small, and our results were deemed robust because of the additional effect in Japanese patients compared with that in the global population according to the subanalysis of Japanese patients in the trial. Therefore, based on an adaptation of a published Markov model, apixaban is a cost-effective alternative to warfarin in Japan for stroke prevention among patients with NVAF.

show abstract

“…Data from various previous trials were used to define quality of life (QOL). 22- 27 The QOL was 0.8 in new CAD patients and 0.52 in new stroke patients. Following the Japanese guidelines, the utility values were annually reduced by 2%.…”

Section: Time Horizonmentioning

confidence: 97%

Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan

Kodera

Morita

Kiyosue

et al. 2018

Circ J

View full text Add to dashboard Cite

Background: The addition of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to statin therapy reduces the rate of cardiovascular events. This study examined the cost-effectiveness of PCSK9 inhibitor+statin compared with standard therapy (statin monotherapy) in the treatment of triple-vessel coronary artery disease (CAD) in Japan. Methods and Results:A Markov model was applied to assess the costs and benefits associated with PCSK9 inhibitor+statin over a projected 30-year period from the perspective of a public healthcare payer in Japan. The incremental cost-effectiveness ratio (ICER), expressed as the quality-adjusted life-years (QALYs), was estimated. The effects on survival and numbers of events were based on the FOURIER trial and the CREDO Kyoto registry. The ICER of PCSK9 inhibitor+statin over standard therapy was 13.5 million (95% confidence interval 7.6-23.5 million) Japanese Yen (JPY) per QALY gained for triple-vessel CAD. The probability of the cost-effectiveness of PCSK9 inhibitor+statin vs. standard therapy was 0.0008% at a cost-effectiveness threshold of 5 million JPY. In patients with poorly controlled familial hypercholesterolemia (FH) with triple-vessel CAD, the ICER was 3.4 million JPY per QALY gained.Conclusions: PCSK9 inhibitor plus statin did not show good cost-effectiveness for triple-vessel CAD; however, it showed good cost-effectiveness for patients with triple-vessel CAD and poorly controlled FH in Japan.

show abstract

Japanese Population Norms for Preference-Based Measures: Eq-5d-3l, Eq-5d-5l, And Sf-6d

Cited by 50 publications

References 0 publications

A Comparison of the EQ-5D-3L and EQ-5D-5L

A Comparison of the EQ-5D-3L and EQ-5D-5L

Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan

Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan

Contact Info

Product

Resources

About